Lung Cancer Clinical Trials in Austin

Showing 381-400 of 598 trials

Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

NCT00372073

A phase 2 study to evaluate efficacy of oral seliciclib in treating non-small cell lung cancer (NSCLC).

Cyclacel Pharmaceuticals, Inc.187 participantsStarted Aug 2006

Tucson, Arizona, United States • Fountain Valley, California, United States • New Port Richey, Florida, United States +17 more locations

COMPLETEDPhase 174 miles

A Study of PLX2853 in Advanced Malignancies.

NCT03297424

The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced malignancies.

Small Cell Lung CancerUveal MelanomaOvarian Clear Cell Carcinoma+5 more

Opna Bio LLC49 participantsStarted Sep 2017

Scottsdale, Arizona, United States • Miami, Florida, United States • New York, New York, United States +2 more locations

Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

A Study of PLX2853 in Advanced Malignancies.

Lung Cancer Trials in Other Cities

A Study of APG-1252 in Patients With SCLC or Other Solid Tumors

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

A Study of LY3023414 in Participants With Advanced Cancer

PEN-866 in Patients With Advanced Solid Malignancies

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC

Safety Study of MGA271 in Refractory Cancer

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

Other Conditions in Austin